CpG methylation in the DAPK1 promoter region has been detected in a range of solid cancers, such as non-small cell lung cancer (34), leiomyosarcoma (35), nasopharyngeal carcinoma (36), and hematological malignancies, such as follicular lymphoma (37) and CML (24,25,38). This evidence concerns the gene DAPK1 and chronic myelogenous leukemia, BCR-ABL1 positive.